icon-folder.gif   Conference Reports for NATAP  
 
  18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C
Back grey_arrow_rt.gif
 
 
 
HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough) in PATIENTS presenting SIDE EFFECTS : INTEREST of THERAPEUTIC DRUG MONITORING ?
 
 
  Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy 14-16 June 2017, Chicago, USA
 
C SOLAS1, S BREGIGEON2, O FAUCHER-ZAEGEL2, H LAROCHE2, V OBRY-ROGUET2, S QUARANTA3, C TAMALET4, B CANET2, B LACARELLE1, I POIZOT-MARTIN2,5 1Aix Marseille Univ, APHM La Timone, Pharmacokinetics and Toxicology-Inserm U911-CRO2 SMARTc, Marseille, France; 2APHM Sainte-Marguerite, Clinical Immuno-Hematology, Marseille, France; 3AP-HM La Timone, Pharmacokinetics and Toxicology, Marseille. France; 4IHU Mediterranee Infection, Aix Marseille Univ, APHM, URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095, Marseille, France; 5Aix Marseille Univ, Inserm U912-SESSTIM, Marseille, France

EASL1

EASL2

EASL3

References:
(1): de Boer M. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016
(2): Hoffmann C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017